Resources
12 Results (showing 1 - 10)
Results sorted by updated date (oldest first)
Results sorted by updated date (oldest first)
Posted 12/20/2021 (updated 3/26/2024)
The Centers for Disease Control and Prevention (CDC) want greater awareness of adverse childhood experiences (ACEs) and their connection to high rates of overdose and suicide. This week they announced a new training webpage, UrgentRelatedPreventable.org, designed in collaboration with the American Public Health Association to provide background and talking points. The site explains how exposure to certain events and conditions in childhood have lasting effects on health, well-being, and prosperity far into adulthood. See Funding section below for a CDC effort to research the links between ACEs and substance use.
Posted 3/15/2022 (updated 3/27/2024)
This TIP reviews three Food and Drug Administration-approved medications for opioid use disorder treatment—methadone, naltrexone, and buprenorphine—and the other strategies and services needed to support people in recovery.
Posted 10/10/2023 (updated 3/27/2024)
The University of Rochester, a RCORP-Rural Center of Excellence on SUD Prevention, has 988 Lifeline posters available for download on their website. The national 988 Suicide & Crisis Lifeline was launched in July 2023 and provides a way for individuals experiencing a suicidal, mental health, or substance use disorder crisis to receive urgent help 24/7. Spreading awareness of the 988 Lifeline is important as it can help residents in rural areas obtain treatment and help quickly.
Posted 2/13/2024 (updated 3/28/2024)
Dr. Ashli Sheidow will discuss this age group and some of the considerations for designing services for them, especially within a rural context.
Posted 7/28/2021 (updated 4/2/2024)
Various state and local jurisdictions in the United States are implementing mobile models for treating opioid use disorder (OUD). In August 2020, RTI International spoke with six agencies to learn more about their mobile treatment programs. This article is the first in a three-part series on mobile response programs and provides an in-depth look at two of these programs. We will discuss the remaining programs in two subsequent articles. The goal of this series is to inform jurisdictions considering whether a mobile treatment program would work in their communities and to determine what type of model would fit best.
Posted 7/28/2021 (updated 4/2/2024)
The most effective treatments for opioid use disorder (OUD) are the three prescription medications approved by the U.S. Food and Drug Administration (FDA)—methadone, buprenorphine, and naltrexone—that are proved to increase a patient’s treatment retention and reduce illicit use and the risk of overdose. The only facilities legally able to offer all three medications are opioid treatment programs (OTPs), a critical component of the U.S. substance use treatment system that are regulated by the federal Drug Enforcement Administration (DEA) and Substance Abuse and Mental Health Services Administration (SAMHSA), as well as state agencies, and are certified to administer any FDA-approved medication for the treatment of OUD.
Posted 9/1/2021 (updated 4/2/2024)
Posted 9/1/2021 (updated 4/2/2024)
Posted 11/18/2020 (updated 4/3/2024)
Pharmacists can play an important role in improving access to medication for opioid use disorder (MOUD), especially for individuals living in rural areas where health care workforce shortages are pervasive. Learn how pharmacists can provide Medication Administration Services (MAS) and establish Collaborative Practice Agreements (CPA) in coordination with one or more treating health care providers.
Posted 12/9/2020 (updated 4/3/2024)
State policymakers are interested in learning about the most effective treatments to address OUD and avoid unintended consequences such as overdose events, mortality from overdose, and use of illicit and unregulated drugs. This article describes the lack of evidence surrounding the use of Medically Supervised Withdrawal as a standalone “treatment.”